Neurotensin receptors in pancreatic ductal carcinomas

Meike Körner1, Beatrice Waser1, Oliver Strobel2, Markus Büchler2 and Jean Claude Reubi1*

Abstract

Background: The frequent expression of neurotensin receptors (NT-R) in primaries of pancreatic ductal carcinomas has triggered the development of radioactive neurotensin analogs for possible in vivo targeting of these tumors. However, the complete lack of information regarding NT-R in liver metastases of pancreatic cancer and pancreatic intraepithelial neoplasia (PanIN) makes an in vitro study of NT-R in these tissues indispensable.

Methods: Using in vitro receptor autoradiography with 125I-[Tyr3]-neurotensin, NT-R were investigated in 18 primaries and 23 liver metastases of pancreatic ductal carcinomas as well as in 19 PanIN lesions.

Results: We report here that 13 of 18 ductal carcinoma primaries and 14 of 23 liver metastases expressed NT-R. Moreover, none of the six PanIN 1B cases expressed NT-R, while two of six PanIN 2 and five of seven PanIN 3 expressed NT-R. Binding was fully displaced by the type 1 NT-R-selective antagonist SR48692, indicating that the NT-R in the tumors are of the type 1 NT-R subtype.

Conclusions: These in vitro data extend the currently available information on NT-R in invasive and non-invasive pancreatic ductal tumors. They suggest that type 1 NT-R may be a novel, specific marker of PanIN of higher degree. The high expression of NT-R in primaries and metastases of invasive cancer strongly support the need to develop radioactive neurotensin analogs for the diagnosis and therapy of this tumor type.

Keywords: Neurotensin receptors; Pancreatic ductal carcinomas; Liver metastasis; Pancreatic intraepithelial neoplasia; Tumor imaging

Background

Two decades ago, neurotensin receptors (NT-R) were found to be expressed in approximately 75% of primary pancreatic ductal adenocarcinomas by NT-R autoradiography [1]. The NT-R were present in high density in the tumor cells, while the non-neoplastic pancreatic ducts did not express NT-R [1]. This suggested for the first time the possibility to specifically target pancreatic tumor cells via NT-R [1]. These expression data were confirmed by Ehlers et al. showing an approximately 90% incidence of NT-R in pancreatic cancers by RT-PCR measurement [2]. Later on, several groups identified NT-R in various other cancer types [3-7]. The role and function of the NT-R in cancer has also been investigated in the past one to two decades [8,9]. It appears to be clear that NT-R (especially the type 1 NT-R (also named NTS1 [10])) mediate a proliferative action of neurotensin in pancreatic cancer and also in other tumors [9,11-14]. There is also strong evidence that the type 1 NT-R-selective antagonist SR48692 [15] can inhibit tumoral proliferation [12-14]. Therefore, the use of neurotensin analogs has been proposed as strategy for the antiproliferative treatment of pancreatic cancer [3,8,16,17].

On the other hand, these in vitro receptor expression data [1,2] also triggered the development of radioactive neurotensin analogs that could be used for the visualization and, eventually, targeted radiotherapy of pancreatic ductal adenocarcinoma and other tumors. The majority of the published compounds are radiolabeled NT-R agonists [18-24], but radiolabeled NT-R antagonists have recently appeared [25,26]. Proof of principle that pancreatic ductal carcinomas can be visualized in patients with radiolabeled NT-R agonists was provided in preliminary studies [27-29]. Indeed, it would be important to have a reliable non-invasive tool permitting to visualize the majority of
pancreatic ductal carcinomas in patients. It would be equally important to be able to treat the patients that have a receptor-positive carcinoma by giving them a radiotherapeutic dose of the radiolabeled neurotensin; many of the patients diagnosed with pancreatic ductal carcinomas already have or will soon have metastatic disease. Most patients die due to systemic disease within a short period of time after resection [30].

A targeted therapy of pancreatic cancer would, however, make sense only if all tumor manifestations in a given patient, namely the primary and the metastases, express NT-R. Considering the frequent observation of tumor heterogeneity in cancer in general, in terms of both histopathological features and of biological parameters, it is not possible to simply extrapolate that NT-R-positive primary pancreatic ductal carcinomas will give rise to NT-R-positive metastases. Unfortunately, there are presently no experimental data indicating whether metastases of ductal pancreatic carcinomas express NT-R. This lack of information is due in part to the fact that these metastases are not operated and that metastasis material is hardly available for in vitro investigations. In the present study, we have been able to investigate a significant number of metastases of ductal pancreatic carcinomas, sometimes together with their primaries, using NT-R autoradiography. To complete the study, we have also investigated NT-R in non-invasive, intraductal neoplasia (PanIN) using the same methodology.

Methods

Tissues
Pancreatic ductal carcinoma samples were collected at the Department of General, Visceral and Transplantation Surgery, University Hospital Heidelberg, Heidelberg, Germany, and at the Institute of Pathology, University of Bern, Bern, Switzerland. The number and types of tissues investigated are listed in Tables 1 and 2. All tissues were frozen in liquid nitrogen or in dry ice immediately after surgical resection and stored at −70°C. Informed consent was available for all patients. The study collection conformed to the ethical guidelines of both centers and was reviewed by the Institutional Review Boards of University Hospital Heidelberg and University of Bern.

NT-R autoradiography
Receptor autoradiography was performed on 20-μm-thick cryostat (Microm HM550, Thermo Fisher Scientific, Walldorf, Germany) sections of the tissue samples, mounted on microscopic slides and then stored at −20°C for at least 3 days to improve adhesion of the tissue to the slide. Sections were pre-incubated in 50 mM Tris–HCl pH 7.4 with 0.02% BSA for 3 times at 5 min at 20°C. Slides were then incubated in 50 mM Tris–HCl pH 7.4 containing 0.02% BSA, 1 mM o-phenantroline, 1 mM MgCl₂ and 40,000 dpm/100 μl (corresponding to 90 pM) ¹²⁵I-[Tyr³]-Neurotensin (2,000 Ci/mmol; ANAWA, Wangen, Switzerland) for 1 h at room temperature. Additional sections were incubated in the presence of 100 nM non-radioactive neurotensin (Bachem, Bubendorf, Switzerland) to assess non-specific binding, as well as in the presence of 1,000 nM of the type 1 NT-R-selective analog SR48692 (Sanofi, Paris, France), for NT-R subtyping. After incubation, the slides were washed for 10 min at 4 °C in four consecutive baths containing 50 mM Tris–HCl pH 7.4 with 0.02% BSA. After a brief dip in buffer without BSA, the sections were dried under a stream of cold air and then exposed to Kodak (Rochester, NY, USA) films Biomax MR for 7 days at 4 °C. The autoradiograms were quantified using a computer-assisted image processing system (Analysis Imaging System, InterFocus, Mering, Germany). Tissue standards for iodinated compounds (Amersham, Aylesbury, UK) were used for this purpose [1,4].

Results and discussion
Table 1 summarizes the data of NT-R incidence and density in pancreatic ductal carcinoma patients. The results are divided into three groups, depending on the availability of the respective frozen tissue: (1) primaries only, (2) primary and liver metastasis of the same patient, and (3) metastases only. It can be seen that not only primaries do often express NT-R in high density but also the liver metastases. The overall incidences of NT-R expression are 73% (8 of 11 cases) in primaries and 63% (14 of 23 cases) in metastases. Interestingly, all NT-R-expressing tumors have a high receptor density, namely above 3,000 dpm/mg tissue. From the six patients of whom primary and metastasis are available, three have high NT-R expression in both primary and metastasis, two have high expression in the primary only, and one is receptor-negative in both. This latter case had chemotherapy (gemcitabine) prior to the surgical resection. It cannot, however, be concluded definitely that chemotherapy is responsible for the lack of NT-R, since another chemotherapy-treated patient (Table 1) had a high NT-R expression over 6,000 dpm/mg tissue in his tumor. As also stated in Table 1, we have also performed displacement experiments with incubation of the ¹²⁵I-[Tyr³]-neurotensin radioligand in the presence of 1,000 nM of the cold type 1 NT-R-selective analog SR48692. In the tested cases listed in Table 1, radioligand binding could be completely displaced by SR48692 indicating the presence of the type 1 NT-R subtype in these tissues. Three tumors (No. 11, 26, 27) could not be tested for SR48692 due to lack of tissue. Figure 1 illustrates a case of a patient with high NT-R expression in both the primary and the liver metastasis. Here, the NT-R are densely and homogeneously...
distributed in both tumor manifestations. The adjacent normal pancreas and liver, respectively, are NT-R-negative.

Table 2 shows samples of additional pancreatic ductal tumor patients with resected pancreatic tissue containing various stages of PanIN with or without the corresponding invasive ductal carcinoma. Here, there is a clear difference in NT-R expression depending on the PanIN stage: None of the six PanIN 1B cases expresses NT-R, and only two out of the six PanIN 2 cases express NT-R, whereas the majority of the PanIN 3 cases (five out of seven cases) express NT-R. Interesting is the observation that in the two latter NT-R-negative PanIN 3 patients, their corresponding invasive ductal carcinomas (and their PanIN 1B and 2 stages as well) are also NT-R-negative. In three other cases, we see the NT-R expressed in PanIN 3 stages as well as in invasive ductal carcinomas, while adjacent PanIN 1B and/or PanIN 2 stages in these patients are NT-R-negative. Figure 2 illustrates the NT-R status in various PanIN lesions.

| Patient number | Primary | Receptor density dpm/mg tissue | Metastasis | Receptor density dpm/mg tissue | Comments |
|----------------|---------|--------------------------------|------------|--------------------------------|----------|
|                |         | Receptor density dpm/mg tissue |            | Receptor density dpm/mg tissue |          |
| Primary only   |         |                                |            |                                |          |
| 1              | 8,335 (9,392; 7,278)* |                                |            |                                |          |
| 2              | 0                                  |                                |            |                                |          |
| 3              | 0                                  |                                |            |                                |          |
| 4              | 6,194 (6,317; 6,071) het*          |                                |            |                                |          |
| 5              | 9,600 (9,301; 9,899)*              |                                |            |                                |          |
| Primary + metastasis of same patient |         |                                |            |                                |          |
| 6              | 9,310 (9,157; 9,462) het*          |                                |            |                                |          |
| 7              | 3,053 (2,953; 3,152) het*          |                                | 3,982 (4,584; 3,379) het*     |          |
| 8              | 10,274 (10,626; 9,921)*           |                                | 5,084 (5,174; 4,993) het*     |          |
| 9              | 0                                  |                                | 0                                  |          |
| 10             | 0                                  |                                | 0                                  | Chemotherapy before resection |
| 11             | 6,145 (6,405; 5,884)               |                                | 4,482 (4,978; 3,986)           |          |
| Metastasis only|         |                                |            |                                |          |
| 12             | 10,866 (11,013; 10,719)*          |                                |            |                                |          |
| 13             | 8,611 (8,189; 9,033)*             |                                |            |                                |          |
| 14             | 8,517 (8,791; 8,243)*             |                                |            |                                |          |
| 15             | 0                                  |                                |            |                                |          |
| 16             | 0                                  |                                |            |                                |          |
| 17             | 6,124 (6,075; 6,172) het*          |                                |            |                                | Chemotherapy before resection |
| 18             | 13,207 (13,169; 13,245)*          |                                |            |                                |          |
| 19             | 13,235 (13,047; 13,422)*          |                                |            |                                |          |
| 20             | 9,753 (9,872; 9,634)*             |                                |            |                                |          |
| 21             | 0                                  |                                |            |                                |          |
| 22             | 6,842 (8,250; 5,433)*             |                                |            |                                |          |
| 23             | 10,684 (12,298; 9,070)*           |                                |            |                                |          |
| 24             | 0                                  |                                |            |                                |          |
| 25             | 0                                  |                                |            |                                |          |
| 26             | 7,671 (7,259; 8,083)              |                                |            |                                |          |
| 27             | 7,828 (7,959; 7,697)              |                                |            |                                |          |
| 28             | 0                                  |                                |            |                                |          |
| Mean ± SEM of positive cancers | 7,367 ± 860 |                                | 8,349 ± 791 |                                |          |
| Total incidence | 8/11 (73%) |                                | 14/23 (61%) |                                |          |

het, heterogeneous NT-R distribution. Values represent NT-R density (dpm per mg tissue) as mean of two separate experiments with individual values in parenthesis.
*In addition to the displacement by neurotensin, full displacement by SR48692 was observed in these tumors.
As seen in Table 2, we have performed in the NT-R-expressing PanIN 2 and PanIN 3 and invasive ductal cancer cases displacement experiments with incubation of the $^{125}\text{I}$-[Tyr$^3$]-neurotensin radioligand in presence of 1,000 nM of the cold type 1 NT-R-selective analog SR48692. In all cases, radioligand binding could be completely displaced by SR48692, reaching low binding levels corresponding to non-specific binding, similar to that identified in the presence of 100 nM cold neurotensin. This is illustrated in Figure 3 for a PanIN 3 lesion and an adenocarcinoma. This set of experiments indicates that the NT-R in these tissues are of the type 1 subtype.

This study confirms on the one hand that pancreatic ductal cancers frequently express a high density of NT-R, as reported previously [1,2]. However, it expands this information in two ways: (1) it clearly shows that liver metastasis lacks NT-R, (2) it also shows that liver metastasis lacks NT-R.

| Patient number | PanIN 1B | PanIN 2 | PanIN 3 | Invasive ductal carcinoma$^b$
|----------------|---------|---------|---------|------------------------
| 29             | -       | 1,882 (1,732;1,923)$^a$ | -       | -                     |
| 30             | -       | -       | 5,809 (5,937;5,681)$^a$ | 1,257 (1,290;1,223)$^a$ |
| 31             | 0       | -       | -       | -                     |
| 32             | 0       | 0       | -       | -                     |
| 33             | -       | >10,000 (>10,000;>10,000)$^a$ | 9,871 (9,741;10,000)$^a$ | 8,769 (8,885;8,652)$^a$ |
| 34             | 0       | -       | 1,937 (1,881;1,992)$^a$ | 1,651 (1,759;1,542)$^a$ |
| 35             | -       | 0       | 3,103 (3,209;2,996)$^a$ | 2,539 (2,771;2,306)$^a$ |
| 36             | 0       | 0       | -       | -                     |
| 37             | 0       | -       | 9,988 (9,976;10,000)$^a$ | >10,000 (>10,000;>10,000)$^a$ |
| 38             | 0       | 0       | -       | -                     |
| Mean ± SEM of positive cases | 0 | 5,914 ± 4,086 | 6,142 ± 1,669 | 4,843 ± 1,876 |

Values represent neurotensin receptor density (dpm/mg tissue). $^a$ In addition to the displacement by neurotensin, full displacement by SR48692 was observed in these tissues. $^b$ These cases are different from those listed in Table 1. Hyphen (−) means no corresponding tissue available.

As seen in Table 2, we have performed in the NT-R-expressing PanIN 2 and PanIN 3 and invasive ductal cancer cases displacement experiments with incubation of the $^{125}\text{I}$-[Tyr$^3$]-neurotensin radioligand in presence of 1,000 nM of the cold type 1 NT-R-selective analog SR48692. In all cases, radioligand binding could be completely displaced by SR48692, reaching low binding levels corresponding to non-specific binding, similar to that identified in the presence of 100 nM cold neurotensin. This is illustrated in Figure 3 for a PanIN 3 lesion and an adenocarcinoma. This set of experiments indicates that the NT-R in these tissues are of the type 1 subtype.

This study confirms on the one hand that pancreatic ductal cancers frequently express a high density of NT-R, as reported previously [1,2]. However, it expands this information in two ways: (1) it clearly shows that liver metastasis lacks NT-R, (2) it also shows that liver metastasis lacks NT-R.

| Figure 1 Expression of NT-R by in vitro receptor autoradiography. | NT-R expressed in a ductal pancreatic carcinoma: primary (A-C) and liver metastasis (D-F). As negative control, a NT-R-negative liver metastasis is also shown (G-I). (A), (D), (G) Hematoxylin-eosin-stained sections showing tumor tissue (Tu) and the adjacent pancreas (P) or liver (L), respectively. Bars = 1 mm. (B), (E) Autoradiograms showing total binding of $^{125}\text{I}$-[Tyr$^3$]-neurotensin. High density of NT-R is found in the tumors but not in the pancreas or liver. (H) Autoradiogram showing total binding of $^{125}\text{I}$-neurotensin. This metastasis lacks NT-R. (C), (F), (I) Autoradiograms showing non-specific binding of $^{125}\text{I}$-[Tyr$^3$]-neurotensin (in the presence of 100 nM neurotensin). |
Figure 2 NT-R in vitro receptor autoradiography in PanIN. In vitro receptor autoradiography of NT-R in various PanIN, PanIN 1B (A-C), PanIN 2 (D-F), and PanIN 3 (G-I), and in invasive cancer (J-L). (A), (D), (G), (J) Hematoxylin-eosin-stained sections (bars = 0.1 mm), including inset of representative area at high magnification. (B), (E), (H), (K) Autoradiograms showing total binding of \(^{125}\text{I}-[\text{Tyr}^3]\)-neurotensin. While the PanIN 1 case (B) is NT-R-negative, PanIN 2 (E), PanIN 3 (H), and invasive cancer (K) are NT-R-positive. (C), (F), (I), (L) Autoradiograms showing non-specific binding of \(^{125}\text{I}-[\text{Tyr}^3]\)-neurotensin (in the presence of 100 nM neurotensin).

Figure 3 Autoradiography of NT-R and competition by SR48692. NT-R autoradiography of PanIN 3 (A-D) and of an adenocarcinoma (E-H) with neurotensin and the type 1 NT-R-selective SR48692 as displacer. (A), (E) Hematoxylin-eosin-stained sections (bars = 0.1 mm). (B), (F) Autoradiograms showing total binding of \(^{125}\text{I}-[\text{Tyr}^3]\)-neurotensin. (C), (G) Autoradiograms showing non-specific binding (in the presence of 100 nM neurotensin). (D), (H) Autoradiograms showing full displacement of \(^{125}\text{I}-[\text{Tyr}^3]\)-neurotensin binding in the presence of 1,000 nM SR48692. The detected NT-R are therefore the type 1 NT-R.
metastases also frequently express NT-R in high amounts. It thus closes an information gap and has clinical significance: indeed, the current knowledge of a NT-R expression solely in primaries would not be sufficient to legitimate NT-R targeted diagnostic or therapeutic interventions, since many of ductal pancreatic patients have metastases at the time of diagnosis. (2) The study also provides novel information on NT-R expression in putative pancreatic cancer precursor lesions, namely PanIN. It suggests an increase in NT-R expression from PanIN 1B to PanIN 3, with PanIN 1B completely lacking NT-R, as it is the case for normal pancreatic ducts [1], while PanIN 3 frequently expresses NT-R in high amounts. It is further of interest that in cases with NT-R-expressing PanIN 3, accompanying primary carcinomas also express NT-R, in line with the concomitant expression of many other biologic markers in high-grade PanIN and invasive cancer. Therefore, NT-R, in particular the type 1 NT-R detected in this study, may be considered as a novel, specific marker of pancreatic intraepithelial neoplasia of higher degree.

These data may have potential clinical implications. Indeed, knowing that NT stimulates pancreatic tumor growth [11,13,14] and that the type 1 NT-R-selective antagonist SR48692 inhibits tumor cell proliferation [13], it could be speculated that type 1 NT-R antagonists may be used for treatment of pancreatic cancer primaries, but also of their liver metastases and, speculatively, of the putative cancer precursors, the NT-R-expressing PanIN 2 and 3.

The data may also have more immediate diagnostic and radiotherapeutic implications. There are several newly designed neurotensin analogs which can be labeled with radioactive compounds [18,20,21,23] and that can be used either for SPECT or for PET diagnostic evaluation. Preliminary clinical evaluation was performed with two of them, however, with limited success probably due to rapid degradation of the tracers [27,28]. Recently, in line with the observation that somatostatin and bombesin receptor antagonists may be advantageous for tumor radiotargeting [31-34], radiolabeled NT-R antagonists have been developed aimed at greater metabolic stability, less side effects than agonists, and increased tumor uptake compared with agonists [25,26,29]. Such radioactive neurotensin analogs may become useful as diagnostics for the visualization of primary pancreatic carcinoma and their metastases and therefore help to decide on the therapeutic strategy. These radiolabeled neurotensin antagonists may also be used for targeted radiotherapy of primaries and metastases, in particular since the NT-R expression is often very high. Moreover, at the same time, the putative precursor lesions, the NT-R-expressing PanIN 2 and PanIN 3, may also be destroyed. The amount of NT-R expressed in all these lesions appears clearly high enough for such a clinical application.

Conclusions

These in vitro data extend the currently available information on NT-R in invasive and non-invasive pancreatic ductal tumors. They suggest that type 1 NT-R may be a novel, specific marker of PanIN of higher degree. The high expression of NT-R in primaries and metastases of invasive cancer strongly support the need to develop radioactive neurotensin analogs for the diagnosis and therapy of this tumor type.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

MK analyzed and interpreted the data, BW performed all experiments, OS and MB selected and provided the tissues and reviewed the manuscript, and JCR designed the study, analyzed the data, and wrote the manuscript. All authors read and approved the manuscript.

Author details

1. Cell Biology and Experimental Cancer Research, Institute of Pathology, University of Berne, PO Box 62, Murtenstrasse 31, CH-3010 Berne, Switzerland.
2. Department of General, Visceral and Transplantation Surgery, University Hospital Heidelberg, Heidelberg, Germany.

Received: 3 February 2015 Accepted: 26 February 2015
Published online: 24 March 2015

References

1. Reubi JC, Waser B, Friess H, Büchler MW, Laissue JA. Neurotensin receptors: a new marker for human ductal pancreatic adenocarcinoma. Gut. 1998;42:546-50.
2. Ehlers RA, Kim S, Zhang Y, Ehtridge RT, Murillo C, Hellmich MR, et al. Gut peptide receptor expression in human pancreatic cancers. Ann Surg. 2000;231:838-48.
3. Carraway RE, Plora AM. Involvement of neurotensin in cancer growth: evidence, mechanisms and development of diagnostic tools. Peptides. 2006;27:2445-60.
4. Reubi JC, Waser B, Scher JC, Laissue JA. Neurotensin receptors in human neoplasms: high incidence in Ewing sarcomas. Int J Cancer. 1999;82:213-8.
5. Gromova P, Rubin BP, Thys A, Emeux C, Vandenwinden JM. Neurotensin receptor 1 is expressed in gastrointestinal stromal tumors but not in interstitial cells of Cajal. PLoS One. 2011;6:e14710.
6. Alfiano M, Souaze F, Dupouy S, Camilleri-Broet S, Younes M, Ahmed-Zaid SM, et al. Neurotensin receptor 1 determines the outcome of non-small cell lung cancer. Clin Cancer Res. 2010;16:4401-10.
7. Swift SL, Burns JE, Maitland NJ. Altered expression of neurotensin receptors is associated with the differentiation state of prostate cancer. Cancer Res. 2010;70:347-56.
8. Mustian WC, Rychahou PG, Evers BM. The role of neurotensin in physiologic and pathologic processes. Curr Opin Endocrinol Diabetes Obes. 2011;18:75-82.
9. Thomas RP, Hellmich MR, Townsend Jr CM, Evers BM. Role of gastrointestinal hormones in the proliferation of normal and neoplastic tissues. Endocr Rev. 2003;24:571-99.
10. Vincent JP, Mazella J, Kitajba P. Neurotensin and neurotensin receptors. Trends Pharmacol Sci. 1999;20:302-9.
11. Olzowski U, Hamilton G. Neurotensin signaling induces intracellular alkalization and interleukin-8 expression in human pancreatic cancer cells. Mol Oncol. 2009;3:304-13.
12. Moody TW, Chan DC, Mantey SA, Moreno P, Jensen RT. SR48692 inhibits non-small cell lung cancer proliferation in an EGF receptor-dependent manner. Life Sci. 2014;100:25-34.
13. Wang JG, Li NN, Li HN, Cui L, Wang P. Pancreatic cancer bears overexpression of neurotensin and neurotensin receptor subtype-1 and SR 48692 counteracts neurotensin induced cell proliferation in human pancreatic ductal carcinoma cell line PANc-1. Neuropeptides. 2011;45:151-6.
14. Guha S, Lunn JA, Santiskulvon C, Rozengurt E. Neurotensin stimulates protein kinase C-dependent mitogenic signaling in human pancreatic carcinoma cell line Panc-1. Cancer Res. 2003;63:2379–87.

15. Gully D, Cantor M, Boigegrain R, Jeanjean F, Mollard J, Poncelet M, et al. Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor. Proc Natl Acad Sci U S A. 1995;92:665–9.

16. Evers BM. Neurotensin and growth of normal and neoplastic tissues. Peptides. 2006;27:2424–33.

17. Kitabgi P. Targeting neurotensin receptors with agonists and antagonists for therapeutic purposes. Curr Opin Drug Discov Devel. 2002;5:764–76.

18. Bergmann R, Scheunemann M, Heichert C, Mäding P, Wittrisch H, Kretzschmar M, et al. Biodistribution and catabolism of 18F-labeled neurotensin(8–13) analogs. Nucl Med Biol. 2002;29:61–72.

19. Aishouk F, Prigonon A, Brans L, Jallane A, Mendes S, Talbot JN, et al. Novel DOTA-neurotensin analogues for 111In scintigraphy and 68Ga PET imaging of neurotensin receptor-positive tumors. Bioconjug Chem. 2011;22:1374–85.

20. Garcia-Granado E, Blauenstein P, Blanc A, Maes V, Tourwe D, Schubiger PA. A stable neurotensin-based radiopharmaceutical for targeted imaging and therapy of neurotensin receptor-positive tumours. Eur J Nucl Med Mol Imaging. 2009;36:37–47.

21. Sparr C, Purkayastha N, Yoshinari T, Seebach D, Maschauer S, Prante O, et al. Syntheses, receptor bindings, in vitro and in vivo stabilities and biodistributions of DOTA-neurotensin(8–13) derivatives containing beta-amino acid residues - a lesson about the importance of animal experiments. Chem Biodivers. 2013;10:2101–21.

22. Wu Z, Li L, Liu S, Yakushijin F, Yakushijin K, Horne D, et al. Facile preparation of a thiol-reactive 18F-labeling agent and synthesis of 18F-DEG-VS-NT for PET imaging of a neurotensin receptor-positive tumor. J Nucl Med. 2014;55:1178–84.

23. Nock BA, Nikolopoulou A, Reubi JC, Maes V, Consath P, Tourwe D, et al. Toward stable N(4)-modified neurotensins for NT31-receptor-targeted tumor imaging with (99 m)Tc. J Med Chem. 2006;49:4767–76.

24. De Visser M, Janssen PJ, Srinivasan A, Reubi JC, Waser B, Erion JL, et al. Stabilised (111)In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer. Eur J Nucl Med Mol Imaging. 2003;30:1134–9.

25. Lang C, Maschauer S, Hubner H, Gmeiner P, Prante O. Synthesis and evaluation of a (18F-labeled diarylpyrazole glycosconjugate for the imaging of NT51-positive tumors. J Med Chem. 2013;56:9361–5.

26. Amthauer H, Stebler M, Goldschmidt J, Pethe A, Schütz J, Rohracker M, et al. Neurotensin receptor 1-targeted radionuclide therapy of HT29 xenografts: a randomized treatment study with Lu-177-labeled 3BP. Eur J Nucl Med Mol Imaging. 2014;41:S325. PW016.

27. Buchegger F, Bonvin F, Kosinski M, Schafland AO, Prior J, Reubi JC, et al. Radiolabeled neurotensin analog, (99 m)TcNT-X, evaluated in neurotensin receptor 1-targeted radionuclide therapy of HT29 xenografts: a randomized treatment study with Lu-177-labeled 3BP. Eur J Nucl Med Mol Imaging. 2003;30:1134–9.

28. Gabriel M, Decristoforo C, Woll E, Eisterer W, Noek B, Maina T, et al. 99mTc-demotensin VI: biodistribution and initial clinical results in tumor patients of a pilot/phase I study. Cancer Biother Radiopharm. 2011;26:557–63.

29. Schuchardt C, Kulagni HR, Smerling C, Osterkamp F, Reineke U, et al. First dosimetric results with Lu-177-3BP-227 in a patient with pancreatic cancer. Eur J Nucl Med Mol Imaging. 2014;41:S332. PW049.

30. Hartwig W, Werner J, Jager D, Debus J, Buccheri MW. Improvement of surgical results for pancreatic cancer. Lancet Oncol. 2013;14:e476–85.

31. Cescato R, Maina T, Noek B, Nikolopoulou A, Charalambidis D, Piccand V, et al. Bombesin receptor antagonists may be preferable to agonists for tumor targeting. J Nucl Med. 2008;49:316–43.

32. Ginj M, Zhang H, Waser B, Cesnoc R, Wild D, Wang X, et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci U S A. 2006;103:16436–41.

33. Wild D, Fani M, Fischer R, Del Pozzo L, Kaul F, Krebs S, et al. Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study. J Nucl Med. 2014;55:1248–52.

34. Weiser G, Mansi R, Grosso AL, Schultz-Seemann W, Dumont-Walter RA, Meyer PT, et al. Positron emission tomography (PET) imaging of prostate cancer with a gastrin releasing peptide receptor antagonist—from mice to men. Theranostics. 2014;4:412–9.